Saturday, October 10, 2026

Ebix Stock Over 28% Up In The Last 21 Sessions

Ebix Stock Over 28% Up In The Last 21 Sessions

(VIANEWS) - Shares of Ebix (NASDAQ: EBIX) jumped by a staggering 28.83% in 21 sessions from $12.35 at 2023-04-04, to $15.91 at 16:23 EST on Thursday, following the last session's upward trend. NASDAQ is falling 0.49% to $11,966.40, after three successive sessions in a row of losses.

Ebix's last close was $15.76, 52.84% under its 52-week high of $33.42.

About Ebix

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $2.17.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 7.33. Meaning, the purchaser of the share is investing $7.33 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.22%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Dec 1, 2022, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 1.89%.

Sales Growth

Ebix's sales growth is negative 14% for the present quarter and negative 4.1% for the next.

More news about Ebix (EBIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,365 source documents archived
Query this data → isubstrate.com